Procter & Gamble (PG) stock
NYSE
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $393.6B
- As of Nov 13, 2026
- P/E
- 24.56x
- Trailing twelve months
- P/B
- 7.11x
- Latest reported equity
- P/S
- 4.48x
- Trailing twelve months
- ROE
- 29.0%
- Trailing twelve months
- Dividend yield
- 2.51%
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $393.6B
- As of Nov 13, 2026
- P/E
- 24.56x
- Trailing twelve months
- P/B
- 7.11x
- Latest reported equity
- P/S
- 4.48x
- Trailing twelve months
- ROE
- 29.0%
- Trailing twelve months
- Dividend yield
- 2.51%
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
24.56x
P/B
7.11x
P/S
4.48x
Earnings and dividend metrics▾
Earnings
EPS
$6.91
Earnings per share
BPS
$23.87
Book value per share
ROE
29.0%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $6.91 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $23.87 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 29.0%.
Dividends
Yield
2.51%
Dividend per share
$4.26
Payout ratio
63.8%
Consecutive years
19+ yrs
Yield uses fiscal 2026 dividends · Dividend per share and payout ratio are for fiscal 2026.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $426.00 before tax.
- Payout ratio — 63.8% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 19 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2027 Q1)
Revenue increased 4.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $22.4B+4.0%
$21.7B
Jul–Sep '24
$22.4B
Jul–Sep '25
$23.3B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 22, 2026.
- Earnings per share increased 1.0% from the same quarter a year earlier.
- Revenue increased 4.0% from the same quarter a year earlier.
- Operating income increased 1.4% from the same quarter a year earlier.
- Net income decreased 0.4% from the same quarter a year earlier.
Filed Oct 22, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Abd El Hak HeshamCEO-Baby and Feminine Care · Nov 12, 2026Open-market sale2,250 shares · $379KAvg. price $168.478,968 shares held after
- Schulten AndreChief Financial Officer · Nov 5, 2026Open-market sale30,677 shares · $5.2MAvg. price $16965,618 shares held after
- Santos de Azevedo Juliana MonteiroCEO - Grooming · Nov 5, 2026Open-market sale5,370 shares · $908KAvg. price $16921,361 shares held after
- Schulten AndreChief Financial Officer · Nov 5, 2026Option exercise30,677 shares · $2.4MAvg. price $78.5296,295 shares held after
- Schulten AndreChief Financial Officer · Nov 4, 2026Open-market sale33,624 shares · $5.5MAvg. price $16565,618 shares held after
- Schulten AndreChief Financial Officer · Nov 4, 2026Option exercise33,624 shares · $3.1MAvg. price $91.0799,242 shares held after
- Janzaruk Matthew W.SVP - Chief Accounting Officer · Nov 3, 2026Open-market sale9,479 shares · $1.5MAvg. price $1631,271 shares held after
- Janzaruk Matthew W.SVP - Chief Accounting Officer · Nov 3, 2026Option exercise9,479 shares · $934KAvg. price $98.5510,750 shares held after
- Raman Sundar G.CEO-Fabric Home & Habitat Care · Oct 30, 2026Open-market sale38,253 shares · $6.3MAvg. price $16547,745 shares held after
- Aguilar Moses Victor JavierChf Rsch, Dev & Innov Officer · Oct 30, 2026Open-market sale18,812 shares · $3.1MAvg. price $164.434255,243 shares held after
- Gama PaulCEO- Health Care · Oct 30, 2026Open-market sale2,894 shares · $478KAvg. price $16543,899 shares held after
- Raman Sundar G.CEO-Fabric Home & Habitat Care · Oct 30, 2026Option exercise38,253 shares · $3.8MAvg. price $98.5585,998 shares held after
- Aguilar Moses Victor JavierChf Rsch, Dev & Innov Officer · Oct 30, 2026Option exercise18,812 shares · $1.5MAvg. price $78.5274,055 shares held after
- Jejurikar ShaileshChairman, President and CEO · Oct 23, 2026Open-market sale35,000 shares · $5.7MAvg. price $163.087155,391 shares held after
- Gama PaulCEO- Health Care · Oct 23, 2026Open-market sale4,331 shares · $698KAvg. price $161.2746,793 shares held after
- Purushothaman BalajiChief Human Resources Officer · Oct 23, 2026Open-market sale4,181 shares · $672KAvg. price $160.7111,296 shares held after
- Jejurikar ShaileshChairman, President and CEO · Oct 23, 2026Option exercise35,000 shares · $2.7MAvg. price $78.5290,391 shares held after
- ARNOLD CRAIGDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $04,474 shares held after
- Biggs M. BrettDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $06,900 shares held after
- Subramaniam RajeshDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $07,768 shares held after
- McEvoy AshleyDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $07,666 shares held after
- JIMENEZ JOSEPHDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $038,968 shares held after
- Bonini SheilaDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $05,983 shares held after
- Allen Bertrand MarcDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $012,698 shares held after
- Portman Robert JonesDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $06,685 shares held after
- McCarthy Christine MDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $019,342 shares held after
- Kempczinski Christopher JDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $013,372 shares held after
- Chang AmyDirector · Oct 13, 2026Grant or award1,438 shares · $0Avg. price $018,897 shares held after
- Schulten AndreChief Financial Officer · Oct 5, 2026Open-market sale3,914 shares · $569KAvg. price $145.3465,618 shares held after
- Whaley Susan StreetChief Legal Officer & Secy · Oct 5, 2026Open-market sale2,369 shares · $344KAvg. price $145.3430,730 shares held after
- Gama PaulCEO- Health Care · Oct 5, 2026Open-market sale2,225 shares · $323KAvg. price $145.3451,124 shares held after
- Jejurikar ShaileshChairman, President and CEO · Oct 1, 2026Grant or award16,065 shares · $0Avg. price $055,391 shares held after
- Whaley Susan StreetChief Legal Officer & Secy · Oct 1, 2026Grant or award6,110 shares · $0Avg. price $033,099 shares held after
- Santos de Azevedo Juliana MonteiroCEO - Grooming · Oct 1, 2026Grant or award3,130 shares · $0Avg. price $026,731 shares held after
- Schulten AndreChief Financial Officer · Oct 1, 2026Grant or award6,557 shares · $0Avg. price $069,532 shares held after
- Aguilar Moses Victor JavierChf Rsch, Dev & Innov Officer · Oct 1, 2026Grant or award5,732 shares · $0Avg. price $055,243 shares held after
- Gama PaulCEO- Health Care · Oct 1, 2026Grant or award12,517 shares · $0Avg. price $053,349 shares held after
- ARNOLD CRAIGDirector · Sep 8, 2026Grant or award207 shares · $0Avg. price $03,036 shares held after
- JIMENEZ JOSEPHDirector · Sep 8, 2026Grant or award327 shares · $0Avg. price $037,530 shares held after
- Kempczinski Christopher JDirector · Sep 8, 2026Grant or award250 shares · $0Avg. price $011,934 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KThe company said it closed an underwritten public offering of €750,000,000 November 3, 2026 aggregate principal amount of 3.750% Notes due November 3, 2030, which included the offering.Published Nov 3, 2026 · Filed Nov 3, 2026Read the summary →
- AI summary8-KP&G said on November 2, 2026 it closed an underwritten public offering of $352,231,000 aggregate principal amount of Floating Rate Notes due November 2, 2076.Published Nov 2, 2026 · Filed Nov 2, 2026Read the summary →
- AI summary8-KThe company said it closed the underwritten public offering of $750,000,000 aggregate principal amount of 5.125% Notes due October 30, 2031 and $750,000,000 aggregate principal amount of 5.300% Notes due October 30, 2033, which it issued on October 30, 2026.Published Oct 30, 2026 · Filed Oct 30, 2026Read the summary →
- The company said it closed an underwritten public offering of €750,000,000 November 3, 2026 aggregate principal amount of 3.750% Notes due November 3, 2030, which included the offering.Read the full analysis →
- P&G said on November 2, 2026 it closed an underwritten public offering of $352,231,000 aggregate principal amount of Floating Rate Notes due November 2, 2076.Read the full analysis →
- The company said it closed the underwritten public offering of $750,000,000 aggregate principal amount of 5.125% Notes due October 30, 2031 and $750,000,000 aggregate principal amount of 5.300% Notes due October 30, 2033, which it issued on October 30, 2026.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Procter & Gamble (PG) stock information
NYSE
Procter & Gamble (PG) is listed on NYSE. Its market capitalization is about $393.6B. On trailing-twelve-month earnings the P/E ratio is 24.56, and the P/B ratio is 7.11. Return on equity is 29%. These figures are computed in-house from official filings and are reference information only.
Procter & Gamble — frequently asked questions
- What is the P/E ratio of Procter & Gamble (PG)?
- On a trailing-twelve-month basis, PG trades at a P/E ratio of 24.56. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Procter & Gamble?
- PG has a market capitalization of about $393.6B. The figure moves with the share price and is refreshed each trading day.
- Does Procter & Gamble pay a dividend?
- PG has a dividend yield of about 2.51%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.